Polycythemia secondary prevention: Difference between revisions
Jump to navigation
Jump to search
Homa Najafi (talk | contribs) No edit summary |
Homa Najafi (talk | contribs) No edit summary |
||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Polycythemia}} | {{Polycythemia}} | ||
{{CMG}} {{AE}} | {{CMG}} {{AE}}{{Debduti}} | ||
==Overview== | ==Overview== | ||
There are no established measures for the secondary prevention of [disease name]. | There are no established measures for the secondary prevention of [disease name]. | ||
Line 22: | Line 22: | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Hematology | [[Category:Hematology]] | ||
[[Category:Emergency medicine]] | |||
[[Category:Disease]] | |||
[[Category:Blood disorders]] | |||
[[Category:Up-To-Date]] | |||
{{WS}} | {{WS}} | ||
{{WH}} | {{WH}} |
Revision as of 21:13, 24 September 2020
Polycythemia Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Polycythemia secondary prevention On the Web |
American Roentgen Ray Society Images of Polycythemia secondary prevention |
Risk calculators and risk factors for Polycythemia secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Debduti Mukhopadhyay, M.B.B.S[2]
Overview
There are no established measures for the secondary prevention of [disease name].
OR
Effective measures for the secondary prevention of [disease name] include [strategy 1], [strategy 2], and [strategy 3].
Secondary Prevention
There are no established measures for the secondary prevention of [disease name].
OR
Effective measures for the secondary prevention of [disease name] include:
- [Strategy 1]
- [Strategy 2]
- [Strategy 3]